Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -19.45% is 85% above its 5-year average of -130.35%, near the high end of its 5-year range (-418.50%–-19.45%).
As of the fiscal period ended Tuesday, June 30, 2026. 66.14% above its 12-month average of -57.45%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -19.45%.
RETURN ON INVESTED CAPITAL (ROIC)
-19.45%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-57.45%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-84.09%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-130.35%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-141.05%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+66.14%
CURRENT VS 3Y AVG
+76.87%
CURRENT VS 5Y AVG
+85.08%
CURRENT VS 10Y AVG
+86.21%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.40%
median of 552 covered companies
CURRENT VS SECTOR MEDIAN
+38.04%
vs the sector median at left
Avalo Therapeutics, Inc.
Market Cap
$719.62M
Return on Invested Capital (ROIC)
-19.45%
TTM Avg
-57.45%
3Y Avg
-84.09%
5Y Avg
-130.35%
Market Cap
$716.11M
Return on Invested Capital (ROIC)
-41.63%
TTM Avg
-2189.24%
3Y Avg
-1224.39%
5Y Avg
-874.41%
Market Cap
$715.49M
Return on Invested Capital (ROIC)
6.11%
TTM Avg
9.98%
3Y Avg
8.97%
5Y Avg
8.63%
Market Cap
$715.02M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-136.50%
3Y Avg
-154.74%
5Y Avg
-122.58%
Market Cap
$740.03M
Return on Invested Capital (ROIC)
-36.83%
TTM Avg
-41.75%
3Y Avg
-59.42%
5Y Avg
-51.49%
Market Cap
$745.42M
Return on Invested Capital (ROIC)
-38.92%
TTM Avg
-31.45%
3Y Avg
-27.82%
5Y Avg
-24.27%
Market Cap
$683.14M
Return on Invested Capital (ROIC)
-110.62%
TTM Avg
-99.41%
3Y Avg
-74.42%
5Y Avg
-73.36%
Market Cap
$762.81M
Return on Invested Capital (ROIC)
-12.00%
TTM Avg
-7.53%
3Y Avg
-5.45%
5Y Avg
-2.27%
Market Cap
$764.21M
Return on Invested Capital (ROIC)
-42.83%
TTM Avg
-51.53%
3Y Avg
-51.53%
5Y Avg
-51.53%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $719.62M | -19.45% | -57.45% | -84.09% | -130.35% |
| Anteris Technologies Global Corp. (AVR)vs › | $716.11M | -41.63% | -2189.24% | -1224.39% | -874.41% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.49M | 6.11% | 9.98% | 8.97% | 8.63% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $715.02M | N/A | -136.50% | -154.74% | -122.58% |
| Candel Therapeutics, Inc. (CADL)vs › | $740.03M | -36.83% | -41.75% | -59.42% | -51.49% |
| Design Therapeutics, Inc. (DSGN)vs › | $745.42M | -38.92% | -31.45% | -27.82% | -24.27% |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.14M | -110.62% | -99.41% | -74.42% | -73.36% |
| Cytek Biosciences, Inc. (CTKB)vs › | $762.81M | -12.00% | -7.53% | -5.45% | -2.27% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.21M | -42.83% | -51.53% | -51.53% | -51.53% |
| Geron Corporation (GERN)vs › | $769.83M | -8.34% | -22.82% | -51.67% | -50.32% |
ROIC
-19.5%
ROE
-22.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -19.45% |
| 2026-03-31 | -89.33% |
| 2025-12-31 | -70.45% |
| 2025-09-30 | -56.77% |
| 2025-06-30 | -51.27% |
| 2025-03-31 | -37.87% |
| 2024-12-31 | -47.65% |
| 2024-09-30 | -156.04% |
| 2024-06-30 | -418.50% |
| 2023-12-31 | -143.16% |
| 2023-09-30 | -122.70% |
| 2023-06-30 | -130.23% |
| 2023-03-31 | -113.88% |
| 2022-12-31 | -217.90% |
| 2022-09-30 | -222.06% |
| 2022-06-30 | -398.76% |
| 2022-03-31 | -186.01% |
| 2021-12-31 | -151.81% |
| 2021-09-30 | -191.91% |
| 2021-06-30 | -337.83% |
| 2021-03-31 | -347.48% |
| 2020-12-31 | -453.37% |
| 2020-09-30 | -131.24% |
| 2020-06-30 | -84.90% |
| 2020-03-31 | -140.77% |
| 2019-12-31 | -67.38% |
| 2019-09-30 | -55.07% |
| 2019-06-30 | -102.80% |
| 2019-03-31 | -89.66% |
| 2018-12-31 | -87.20% |
| 2018-09-30 | -86.44% |
| 2018-06-30 | 13.99% |
| 2018-03-31 | 19.95% |
| 2017-12-31 | 37.57% |
| 2017-09-30 | 57.26% |
| 2017-06-30 | -226.78% |
| 2017-03-31 | -562.74% |
| 2016-12-31 | -421.97% |
| 2016-09-30 | -342.43% |
| 2016-06-30 | -140.97% |
| 2016-03-31 | -95.78% |
| 2015-12-31 | -57.89% |
| 2015-09-30 | -579.81% |
| 2015-06-30 | -315.89% |
| 2015-03-31 | -259.77% |
| 2014-12-31 | -185.46% |
